The maladaptive effects of HIV protease inhibitors (lopinavir/ritonavir) on the rat heart

被引：9
|
作者：
Reyskens, Kathleen M. S. E. [1 ]
Essop, M. Faadiel [1 ]
机构：
[1] Univ Stellenbosch, CMRG, Dept Physiol Sci, ZA-7600 Stellenbosch, South Africa
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2013年 / 168卷 / 03期
基金：
新加坡国家研究基金会;
关键词：
HIV-AIDS; HIV protease inhibitors; Cardiovascular diseases; Ischemia-reperfusion; Metabolism;
D O I：
10.1016/j.ijcard.2013.04.128
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：3047 / 3049
页数：4
相关论文
共 50 条
  • [31] Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir
    R.M.W. Hoetelmans
    C.H.W. Koks
    J.H. Beijnen
    P.L. Meenhorst
    J.W. Mulder
    D.M. Burger
    Pharmacy World and Science, 1997, 19 : 159 - 175
  • [32] The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium
    Israr, M.
    Mitchell, D.
    Alam, S.
    Dinello, D.
    Kishel, J. J.
    Meyers, C.
    HIV MEDICINE, 2011, 12 (03) : 145 - 156
  • [33] Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor
    Barber, Tristan J.
    Harrison, Linda
    Asboe, David
    Williams, Ian
    Kirk, Stuart
    Gilson, Richard
    Bansi, Loveleen
    Pillay, Deenan
    Dunn, David
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (04) : 995 - 1000
  • [34] Immunomodulatory effects of two HIV protease inhibitors, Saquinavir and Ritonavir, on lymphocytes from healthy seronegative individuals
    Delmonte, Ottavia M.
    Bertolotto, Gabriella
    Ricotti, Emanuela
    Tovo, Pier-Angelo
    IMMUNOLOGY LETTERS, 2007, 111 (02) : 111 - 115
  • [35] Cost Effectiveness of Lopinavir/Ritonavir Compared with Atazanavir in Antiretroviral-Naive PatientsModelling the Combined Effects of HIV and Heart Disease
    Kit N. Simpson
    Michelle P. Luo
    Elinor C. Chumney
    Martin S. King
    Scott Brun
    Clinical Drug Investigation, 2007, 27 : 67 - 74
  • [36] Lopinavir/ritonavir: towards simplifying therapy in HIV infection
    Kaplan, Susan S.
    Hicks, Charles B.
    FUTURE VIROLOGY, 2006, 1 (03) : 293 - 304
  • [37] Lopinavir/ritonavir vs indinavir/ritonavir in HIV infected patients: Immuno-virological outcome and side effects
    Dragovic, J
    Jevtovic, LJD
    DRUG SAFETY, 2004, 27 (12) : 928 - 928
  • [38] Lopinavir/ritonavir: Appraisal of its use in HIV therapy
    von Hentig, Nils
    DRUGS OF TODAY, 2007, 43 (04) : 221 - 247
  • [39] Administration of lopinavir/ritonavir association during rat pregnancy: maternal and fetal effects
    Kulay, L., Jr.
    Hagemann, C. C.
    Nakamura, M. U.
    Simoes, R. S.
    Moreira de Carvalho, A.
    Oliveira-Filho, R. M.
    Espiridiao, S.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2013, 40 (01): : 151 - 154
  • [40] Modeling metabolic effects of the HIV protease inhibitor Ritonavir in Vitro
    Laurence, Jeffrey
    Modarresi, Rozbeh
    AMERICAN JOURNAL OF PATHOLOGY, 2007, 171 (05): : 1724 - 1724
12345